• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6/6/24 4:15:24 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QLI alert in real time by email
    6-K 1 tm2416649d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2024

     

    Commission File Number: 001-39805

     

    Qilian International Holding Group Ltd

     

    No. 152 Hongliang East 1st Street, No. 1703,

    Tianfu New District, Chengdu, 610200

    People’s Republic of China

    +86-028-64775180

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x Form 40-F ¨

     

     

     

     

     

     

    Changes in Registrant’s Certifying Accountant

     

    On June 6, 2024, the Company’s Audit Committee and Board of Directors approved the proposed appointment of Enrome LLP ("Enrome”) as the Company’s independent registered public accounting firm, dismissing the Company’s previous independent public accounting firm, ZH CPA, LLC (“ZH”) on the same date.

     

    ZH served as the Company’s independent public accounting firm since January 4, 2023. During the Company’s engagement of ZH until June 6, 2024, there were no disagreements between the Company and ZH on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of ZH, would have caused it to make reference to the subject matter of the disagreements in connection with its report on the Company’s consolidated financial statements for such period. During the two most recent fiscal years and through the subsequent interim period preceding the dismissal of ZH, there was none “reportable event” within the meaning of Item 16F(a)(1)(v) of Form 20-F.

     

    During the two most recent fiscal years ended September 30, 2022 and 2023 and any subsequent interim period prior to engaging Enrome neither the Company nor anyone on its behalf consulted Enrome regarding either (i) the application of accounting principles to any proposed or completed transaction, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that Enrome concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 16F(a)(1)(iv) of Form 20-F and the related instructions to Item 16F of Form 20-F) or a reportable event.

     

    The Company has provided ZH with a copy of the disclosures the Company is making in this Current Report on Form 6-K and has filing as Exhibit 16.1 the letter from ZH stating ZH agrees or has no basis to agree or disagree with the disclosures made herein.

     

     

    SUBMITTED HEREWITH

     

    Exhibits:

     

      16.1 Letter from ZH CPA, LLC, dated June 6, 2024

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: June 6, 2024

     

      Qilian International Holding Group Ltd.
         
      By: /s/ Chen Xin
      Name:  Chen Xin
      Title: Chief Executive Officer

     

     

     

     

     

    Get the next $QLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to "BGM"

    CHENGDU, China, Aug. 13, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that effective on August 11, 2024, its Class A ordinary shares will begin trading on the Nasdaq Capital Market under the ticker symbol "BGM". The new ticker symbol will replace the Company's current ticker symbol "QLI." No action by the Company's shareholders is required with respect to the ticker symbol change. The Company's Class A ordinary shares will continue to be listed on the Nasdaq Capital Market and the CUSIP number remains unchanged. About Qilian International Holding Group L

    8/13/24 8:00:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule

    CHENGDU, China, July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on July 10, 2024, NASDAQ notified the Company that it has determined that for the 10 consecutive business days, from June 21, 2024 to July 9, 2024, the closing bid price of the Company's Class A ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter. About Qilian International Holding Group Ltd Qilian International Holding Group Ltd, headquartered in Gansu, China, is

    7/12/24 8:30:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qilian International Holding Group Limited Announces 1 for 5 Reverse Share Split

    CHENGDU, China, June 18, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced today that an 1 for 5 reverse split of its authorized share capital, was approved by the Company's board of directors on May 29, 2023 and will become effective on June 21, 2024. In connection with the reverse share split, the Company's shareholders will receive one new Class A ordinary share or Class B ordinary share of the Company for every five Class A ordinary shares or every five Class B ordinary shares they hold, respectively. The Company's Class A ordinary shares are expected to begi

    6/18/24 8:30:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLI
    SEC Filings

    View All

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6-K - Qilian International Holding Group Ltd (0001779578) (Filer)

    6/6/24 4:15:24 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6-K - Qilian International Holding Group Ltd (0001779578) (Filer)

    6/4/24 9:25:25 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Qilian International Holding Group Ltd.

    EFFECT - Qilian International Holding Group Ltd (0001779578) (Filer)

    5/17/24 12:15:27 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLI
    Financials

    Live finance-specific insights

    View All

    Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders

    JIUQUAN, China, Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd ((the ", Company", NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of $0.05 per ordinary share, payable in cash on or about March 6, 2023, to shareholders of record on February 28, 2023. "Despite the impacts of COVID-19 on us in our last fiscal year, the Company maintained decent operating results and healthy cash flow. We expect better financial results as China announced a rollback of its anti-COVID measures." said Mr. Zhanchang Xin, CEO of the Company. About Qilian International Holding Group Ltd Q

    2/16/23 4:30:00 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care